U.S. stock night trading volatility: Design Therapeutics fell 3.46% in after-hours trading, as positive news failed to counteract market sentiment fluctuations

U.S. Stock Night Market Movements Design Therapeutics fell 3.46% in the night market. Based on recent key news: On May 18, Design Therapeutics announced four-week data from the RESTORE-FA trial, showing significant clinical improvement and biomarker activity of DT-216P2 in patients with Friedreich's ataxia. The drug performed well in the trial with no serious adverse events reported, positively impacting the stock price. On May 18, analysts raised the target price for Design Therapeutics' stock from $19.33 to $20, indicating a potential upside of about 39%. Analysts unanimously gave a "buy" rating, driving the stock price up. On May 17, Design Therapeutics announced it would hold an investor webcast on May 18 to review the RESTORE-FA trial data for DT-216P2, which was positively received by the market, causing stock price fluctuations. The biopharmaceutical industry has been active recently, with significant capital inflows. Stocks with High Trading Volume in the Industry BeiGene rose 1.22% in the night market. Based on recent key news: On May 15, BeiGene actively discussed the unblinding plan for clinical trial data with the FDA to assess efficacy and safety. This move indicates progress in the company's drug development, driving the stock price up. Source: Pharmaceutical Executive Daily On May 15, BeiGene's Beqalzi drug received FDA approval for the treatment of mantle cell lymphoma, enhancing market confidence in the company's product line, leading to a stock price increase. Source: Pharmaceutical Executive Daily On May 15, BeiGene's global operating model was considered to have structural advantages in development costs and patient access, further boosting investor expectations for the company's long-term growth potential. Source: Pharmaceutical Executive Daily The global oncology drug market is becoming increasingly competitive, with changes in the regulatory environment. NTRA rose 0.34% in the night market. Based on recent key news: On May 15, the FDA approved Natera's Signatera CDx as a companion diagnostic device for adjuvant treatment in patients with muscle-invasive bladder cancer. This approval was based on the results of the IMvigor011 Phase III study, significantly extending patients' disease-free survival and overall survival, driving Natera's stock price up. On May 15, Roche's Genentech announced that Tecentriq received FDA approval for adjuvant treatment of bladder cancer, further enhancing market confidence in related therapies, indirectly benefiting Natera On May 15th, Natera announced that its Signatera test showed significant improvement in patient survival rates in trials, enhancing investor confidence in the company's products. Recent policy support for the biotechnology industry has increased. Intellia Therapeutics rose by 0.63%. Based on recent key news: On May 17th, research from Intellia Therapeutics was published in Nature Biotechnology, revealing a new activation mode of the CRISPR-Cas12a system. The study expanded the design space for RNA operations by designing synthetic CRISPR DNA, enhancing the flexibility of the technology. This breakthrough has attracted market attention and driven up stock prices. No other significant news recently. No other significant news recently. Continuous innovation in the field of gene editing technology has garnered high market attention